Clinical Evaluation of the Vital Signs Monitoring System (VSMS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is an observational, cohort-based, single-site, prospective clinical study enrolling up to 100 patients who are hospitalized in the internal ward. There is no control group.
The primary objectives of the study are:
- Evaluate the body temperature measured by the ear unit and validate its accuracy.
- Evaluate the accuracy of SPO2 signals and results by comparing the readings to a gold standard device with a finger sensor.
Evaluate the ECG and respiration signals recorded by the patch device by comparing them to the signals recorded by a patient monitor with standard leads.
The secondary objectives of the study are:
- Usability - evaluate the ease of use of the device by medical staff and patients (e.g., positioning, activation, replacement of patch, understanding processes and requirements).
- Evaluate the signals quality and the patch adherence after 5 - 7 days on the chest.
The study will assess the safety and effectiveness of the Vital Signs Monitoring System (VSMS) for its intended use/proposed indications. Data will be collected while the VSMS is adhered to each patient for the entire hospitalization period, up to 7 days. There is no follow-up required.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Anat Alon
- Phone Number: 972 8-977-9999
- Email: alona@asaf.health.gov.il
Study Contact Backup
- Name: Peter Spiegel
- Email: psiegel@asaf.health.gov.il
Study Locations
-
-
-
P.O. Beer Ya'akov, Zerifin, Israel, 70300
- Recruiting
- Internal Ward B, Aliza Begin Building, Assaf Harofe Hospital (2nd Floor)
-
Contact:
- Anat Alon
- Phone Number: 972 8-977-9999
- Email: alona@asaf.health.gov.il
-
Contact:
- Peter Spiegel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Hospitalized patients of both genders, above 18 years of age, with ASA physical status classified as 1-4. In order to obtain the necessary results, the following shall also define the patient population:
Temperature: 30-50% of subjects shall be febrile, i.e., having:
- An elevated core or rectal temperature of 38.0°C or higher as measured by a clinical thermometer.
- An elevated sublingual temperature of 37.5°C or higher as measured by a clinical thermometer.
- An elevated Axillary temperature of 37.2°C or higher as measured by a clinical thermometer.
SPO2: 10-20% of patients shall have a blood oxygen saturation level of 70-90%.
ECG / Respiration: At least 20% of patients shall have some type of arrhythmia.
Description
Inclusion Criteria:
- Signed written informed consent
- Age above 18 years from both genders
- American Society of Anesthesiologists (ASA) physical status classification of 1-4
- Hospitalized in internal ward
Exclusion Criteria:
- Abuse of alcohol or illicit drugs
- History of mental retardation or any mental disease
- Skin irritation / Atopic dermatitis or any other skin condition in the area of patient's upper chest that might affect his/her ability to adhere the device appropriately
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
VSMS with ear unit
application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
|
The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
|
|
VSMS without ear unit
application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
|
The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Temperature measured in units of Celsius/Fahrenheit
Time Frame: 6-10 days
|
Validation of measurement accuracy of skin temperature as compared to gold standard.
|
6-10 days
|
|
Oxygen Saturation measured in units of percentage peripheral saturated oxygen
Time Frame: 6-10 days
|
Validation of measurement accuracy of peripheral oxygen saturation as compared to gold standard.
|
6-10 days
|
|
.ECG signal recording and Respiration measured in units heart beat per minute
Time Frame: 6-10 days
|
Assess quality of device's recorded ECG and respiration signals as compared to patient monitor with standard leads
|
6-10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of recorded signal
Time Frame: after 5-7 days of device usage
|
Evaluate the quality of recorded signals in time by comparing signal of day 1 with signal in last day of adherence of the patch
|
after 5-7 days of device usage
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Moshe Tishler, Professor, Assaf Harofeh Hospital/Medical Center
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CLN-7.4.7.10.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiration
-
NCT04306757CompletedPositive-Pressure Respiration | Respiration; Artificial
-
NCT01062789Withdrawn
-
NCT07477535Not yet recruitingChild | Functional Capacity | Music | Posture | Respiration Disorder
-
NCT00893087Completed
-
NCT04008875Completed
-
NCT02760147Completed
-
NCT01193023Unknown
-
NCT07611409Active, not recruitingObstructive Airway Diseases
-
NCT04939285Recruiting
Clinical Trials on Vital Signs Monitoring System
-
NCT03764709Unknown
-
NCT06076057RecruitingHeart Rate Monitoring
-
NCT05220306Withdrawn
-
NCT03393585CompletedEmergencies | Tachypnea
-
NCT05910320TerminatedCongenital Heart Disease in Children
-
NCT06269198RecruitingPostoperative Complications | Cancer, Treatment-Related
-
NCT05023356Not yet recruitingAnesthesia | Vital Signs | Monitors
-
NCT01899911CompletedDesaturation of Blood
-
NCT02647073WithdrawnOpioid Use Disorders
-
NCT02518100CompletedAutomated Measurement of Vital Signs